Company: RPTX
Filing Date: 2025-03-31
Form Type: 8-K
Source: 0001193125-25-068880
Chunk: 2

Company: Repare Therapeutics Inc.
Filing Date: 2025-03-31
Form: 8-K
Item: Item 7.01
Chunk 2
---
Item 7.01      Regulation FD Disclosure.  

On March 31, 2025, the Company issued a press release announcing the executive changes discussed above. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form8-Kand is incorporated by reference herein.

The information contained in Item 7.01 of this Current Report on Form8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.